Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Vaneltix Pharma.

    Client Virtual Booth

    VANELTIX PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vaneltix Pharma
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    305 East High Street, Suite 7, Bound Brook, NJ 08805
    Telephone
    Telephone
    (732) 369-5911
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vaneltix.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)

    Details:

    Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.


    Lead Product(s): Lidocaine,Heparin Sodium

    Therapeutic Area: Urology Product Name: Alenura

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Hyloris Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis

    Details:

    Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.


    Lead Product(s): Lidocaine,Heparin Sodium

    Therapeutic Area: Urology Product Name: Alenura

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals

    Deal Size: $6.7 million Upfront Cash: Undisclosed

    Deal Type: Collaboration December 17, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search